Cochrane · systematic review · CD010410
Low dose naltrexone for induction of remission in Crohn's disease
Parker, CE, Nguyen, TM, Segal, D, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyLow dose naltrexone versus placebo for induction of remission in Crohn's disease
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Induction of clinical remission CDAI < 150 Low dose naltrexone vs placebo | RR 1.48 [0.42, 5.24] | 1 study · 34 participants | Low Downgraded: imprecision |
Induction of 70‐point clinical response CDAI Low dose naltrexone vs placebo | RR 2.22 [1.14, 4.32] | 1 study · 34 participants | Low Downgraded: imprecision |
Induction of 5‐point endoscopic response CDEIS Low dose naltrexone vs placebo | RR 2.89 [1.18, 7.08] | 1 study · 34 participants | Low Downgraded: imprecision |
Sleep disturbance (adverse event) Low dose naltrexone vs placebo | RR 0.92 [0.38, 2.2] | 2 studies · 46 participants | Low Downgraded: imprecision |
Withdrawals due to adverse outcomes Low dose naltrexone vs placebo | RR 1.57 [0.23, 10.71] | 2 studies · 46 participants | Low Downgraded: imprecision |
Low dose naltrexone versus placebo for induction of remission in Crohn's disease
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Induction of clinical remission CDAI < 150 Low dose naltrexone vs placebo | RR 1.48 [0.42, 5.24] | 1 study · 34 participants | Low Downgraded: imprecision |
Induction of 70‐point clinical response CDAI Low dose naltrexone vs placebo | RR 2.22 [1.14, 4.32] | 1 study · 34 participants | Low Downgraded: imprecision |
Induction of 5‐point endoscopic response CDEIS Low dose naltrexone vs placebo | RR 2.89 [1.18, 7.08] | 1 study · 34 participants | Low Downgraded: imprecision |
Sleep disturbance (adverse event) Low dose naltrexone vs placebo | RR 0.92 [0.38, 2.2] | 2 studies · 46 participants | Low Downgraded: imprecision |
Withdrawals due to adverse outcomes Low dose naltrexone vs placebo | RR 1.57 [0.23, 10.71] | 2 studies · 46 participants | Low Downgraded: imprecision |